MU inventors have identified plasma extracellular vesicle (EV) and circulating miRNA sequences that act as minimally invasive biomarkers to diagnose Non-Small Cell Lung cancer (NSCLC) and to predict the most effective therapeutic approach.
Lung cancer causes the most cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of these cases. Current lung cancer screening relies on low-dose computed tomography (LDCT) scans. Due to its high false positive rate (23% – 50%), patients receiving a positive reading are sent for a more invasive biopsy procedure to confirm the results.
NSCLC patients will receive chemotherapy and/or immunotherapy, or targeted therapy based on analysis of known mutations in tissue biopsies. Despite this targeted approach to therapy, these cancers often develop drug resistance likely mediated by non-mutational miRNA-mediated mechanisms.
MU inventors have discovered EV (Hsa-miR-184, Let-7b-5p) and circulating (Hsa-miR-22-3p) miRNAs that can robustly discriminate between NSCLC patients and high-risk cancer-free controls. These blood-based miRNA biomarker can be used in isolation or in combination with LDCT to more accurately diagnose NSCLC, and can be used to predict the most effective therapeutic regime.
- NSCLC diagnosis
- Predict treatment efficacy for NSCLC
- Less risk of false positives during diagnosis
- Avoid patient burden of inaccurate diagnosis or ineffective treatment
- Decrease excess medical costs from inaccurate diagnosis or ineffective treatment
Yves Chiswili Chabu
Vadla GP, Daghat B, Patterson N, et al. Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction. Sci Rep. 2022;12(1):6693. Published 2022 Apr 23. doi:10.1038/s41598-022-10598-x
Brian Buntaine, MS, MBA
Senior Manager, Technology Transfer
Name: Brian Buntaine, MS, MBA
Title: Senior Manager, Technology Transfer
Department: MU Technology Advancement Office
Address: Columbia, Missouri 65211